CRC
California Resources Corporation
stock NYSE

Enrollment is complete; labs are crunching biomarker data now. The pooled-study interim hit 92 % CRC sensitivity and 82 % advanced-adenoma capture - numbers that humbled Cologuard.
If those figures hold in the final read-out, Mainz can fast-track ReconAAsense and lock FDA breakthrough designation. Momentum traders will chase afterward; patient buyers set traps today.

ColoAlert buzz cooled after initial CRC data, but today’s grant reignites headlines. Pancreatic cancer carries emotional investor pull and high reimbursement potential—blood tests get premium codes.
ISB’s 50 % co-finance signals confidence and eases burn. Traders who ignored Mainz at $1.40 may scramble near $3 if PancAlert feasibility matches 95 % sensitivity. Position sizing is key, but catalyst calendar just got fatter without share-count expansion.

Balance sheet strengthened overnight; R&D burn rate effectively halved for PancAlert. ColoAlert’s next-gen CRC test already showed 92 % sensitivity, 82 % AA capture. Those metrics beat Cologuard’s polyp detection by miles.
Market values Mainz like a Phase I single-asset gamble, not a dual-program diagnostics house with governmental cash. If you want asymmetric biotech, here’s the dart: downside limited to grant timelines, upside magnified by killer data sets.

Enrollment is complete; labs are crunching biomarker data now. The pooled-study interim hit 92 % CRC sensitivity and 82 % advanced-adenoma capture - numbers that humbled Cologuard.
If those figures hold in the final read-out, Mainz can fast-track ReconAAsense and lock FDA breakthrough designation. Momentum traders will chase afterward; patient buyers set traps today.

ColoAlert buzz cooled after initial CRC data, but today’s grant reignites headlines. Pancreatic cancer carries emotional investor pull and high reimbursement potential—blood tests get premium codes.
ISB’s 50 % co-finance signals confidence and eases burn. Traders who ignored Mainz at $1.40 may scramble near $3 if PancAlert feasibility matches 95 % sensitivity. Position sizing is key, but catalyst calendar just got fatter without share-count expansion.

Balance sheet strengthened overnight; R&D burn rate effectively halved for PancAlert. ColoAlert’s next-gen CRC test already showed 92 % sensitivity, 82 % AA capture. Those metrics beat Cologuard’s polyp detection by miles.
Market values Mainz like a Phase I single-asset gamble, not a dual-program diagnostics house with governmental cash. If you want asymmetric biotech, here’s the dart: downside limited to grant timelines, upside magnified by killer data sets.